Investigation of EGFR-targeted therapies for GBM has been robust and diverse, including anti-EGFR antibody-loaded nanoparticles, anti-EGFRvIII CAR-T therapy, antibody drug conjugates like depatuxizumab mafodotin, and clinical trials investigating monoclonal antibodies or tyrosine kinase inhibitors against EGFR like erlotinib and lapatinib25–29. The gene discussed is EGFR; the disease is glioblastoma.